Matthews China Fund

Matthews Asia Funds

Risk Considerations

  • Investment involves risk. Past performance is not a guide to future performance. It is possible to lose the principal capital of your investment.
  • The Fund invests primarily in China-related companies. Investments in such companies may be subject to increased risks such as political, tax, economic, policy, market, liquidity, trading, custody and settlement, currency, legal and regulatory risks.
  • The Fund invests primarily in equity securities, which may result in increased volatility.
  • The Fund may invest in smaller companies which are likely to carry higher risks than larger companies.
  • The Fund may invest in financial derivative instruments (“FDIs”). Risk associated with FDIs include counterparty/credit risk, liquidity risk, valuation risk, volatility risk and over-the-counter transaction risk. The Fund will not use FDIs extensively for investment purposes.
  • The Fund may use hedging techniques to attempt to offset certain market risks but there is no guarantee that hedging techniques will fully and effectively achieve their desired result.
  • Investors should not invest in the Fund solely based on the information in this website. Please read the Hong Kong Offering Document carefully for further details including risk factors before investing.

Period ended 30 September 2019

For the quarter ending 30 September 2019, the Matthews China Fund returned -4.74%, while its benchmark, the MSCI China Index, returned -4.67%.

Market Environment:

Chinese equities were down in the third quarter, succumbing to trade-related pressure and negative sentiment. U.S.-listed Chinese ADRs were particularly weak amid U.S–China trade tensions. Although the near-term outcome of trade negotiations remains unpredictable, a slowing U.S. economy could put pressure on U.S. President Donald Trump to negotiate as U.S. elections draw closer.

Meanwhile, Hong Kong protests and tensions continued. Looking back to an earlier protest, the umbrella movement of 2014 lasted for several months, so current protests could take time to subside. Notably, the portfolio has limited exposure to companies directly impacted by the protests. Hong Kong protests continued to be prominent in global headlines, contributing to negative sentiment among foreign investors.

On a positive note, domestically listed Chinese stocks, known as A-shares, generated attractive gains year to date, even as returns for Chinese stocks listed in Hong Kong were essentially flat for the same period. The notable divergence in returns indicates a more positive mindset among mainland Chinese investors toward local economic conditions, where domestic consumption remains healthy and continues apace.

Performance Contributors and Detractors:

From a sector perspective, the Fund's holdings in the financials, communication services and consumer discretionary sectors detracted from relative performance. A detractor among individual stocks was Ctrip.com International, a travel booking site. Weakened sentiment on outbound travel from mainland China to Hong Kong and Taiwan due to the Hong Kong protests and government restrictions on individual travel to Taiwan dampened the company's near-term growth prospects. However, we continue to like the company's long-term prospects. Increased demand for travel services is a long-term, secular trend in China and Ctrip continues to diversify its revenue sources in catering to both increasing domestic as well as global travel among Chinese consumers.

Turning to contributors, the Fund's holdings in the health care, information technology and consumer staples sectors contributed to performance. A contributor among individual stocks was Sino Biopharmaceutical, a leading pharmaceutical drug manufacturer in China. Despite the government's push for affordable health care and the overhang of price cuts in generic drugs, Sino Biopharmaceutical has been executing well in terms of diversifying and enhancing its product mix to include more innovative oncology drugs, which have shown considerable growth. The company also has increased its spending on research and development in past years, and we believe it has built a sufficiently strong pipeline to capitalize on the growth of innovative drugs in China in the years ahead.

Notable Portfolio Changes:

During the quarter, we initiated a new position in Frontage Holdings, a health care services company that operates in both the U.S. and China. The company is a contract research organization providing integrated, scientifically driven product-development services throughout the drug discovery and development process that enables pharmaceutical and biotechnology companies to achieve their drug development goals. The company benefits from having operations in both the U.S. and China, the two largest pharmaceutical markets in the world, and is well-placed to capture growth opportunities in both markets.

We also initiated a position in China East Education, a vocational training company based in the eastern provincial capital of Hefei. The company operates schools that train graduates to work in services-based industries, such as food preparation, information technology support and auto-repair services. As services continue to make up the largest part of China's economy, we believe demand for skilled workers in these areas will rise.

During the quarter, we exited several smaller positions while streamlining the portfolio in favor of higher-conviction positions. Companies we exited included semiconductor equipment maker ASM Pacific Technology; fiberglass manufacturer China Jushi; petroleum refinery China Petroleum & Chemical; diary producer Inner Mongolia Yili Industrial; employee recruiter 51Job; and laminate producer Kingboard Holdings. We also exited some streaming media and entertainment companies, including iQiyi, Tencent Music Entertainment, and YY.

Outlook:

Following the reporting period, sales figures during China's semiannual holiday of Golden Week looked resilient as consumers continued to make upgrades in purchases. Domestic tourism remained robust and hotel bookings were up among travelers visiting family members within mainland China. Restaurant revenues also were up during the holidays, another sign of healthy consumer spending.

Meanwhile, U.S.–China trade tensions remain unresolved. The Chinese government continues to balance the long-term goal of deleveraging the economy and maintaining consumption-related growth. Thus far, the government has refrained from launching broad-based measures aimed at boosting growth within the economy. While we believe the pattern of targeted relief aimed at parts of the economy may continue, we also note that policymakers have considerable fiscal ability to step in, if necessary.

Domestic consumption and the growing services sector within China remain the primary drivers of China's growth. We see significant consumption growth coming from China's less-developed urban centers, which are often home to millions of inhabitants per city who have rising incomes and a strong interest to upgrade their quality of life. Our portfolio construction process, designed to identify the most compelling opportunities from the bottom up, will continue to look for quality growth companies with attractive, long-term secular growth potential.


Annual Returns For the Years Ended 31 December
Matthews China Fund 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
I (Acc) (USD) -19.89% 57.70% -3.95% -0.45% -2.95% 6.75% 11.90% -18.00% n.a. n.a.
I (Acc) (GBP) -15.40% 43.82% 15.48% 4.66% 3.00% 4.49% 7.16% n.a. n.a. n.a.
MSCI China Index (USD) -18.75% 54.33% 1.11% -7.62% 8.26% 3.96% 23.10% -18.24% n.a. n.a.

For YTD performance figures, please refer to the Quarterly and Monthly Performance pages.



 

Additional performance, attribution, liquidity, value at risk (VaR), security classification and holdings information is available on request for certain time periods.




There is no guarantee that a company will pay or continue to increase dividends.

Performance figures discussed in any of the Fund Manager Commentaries reflect that of the Institutional Accumulation Class Shares and have been calculated in USD, including ongoing charges and excluding subscription fee and redemption fee investors might have to pay. Performance details provided for the Fund are based on a NAV-to-NAV basis, with any dividends reinvested, and are net of management fees and other expenses.  Past performance information is not indicative of future performance. Investors may not get back the full amount invested.

The information contained herein has been derived from sources believed to be reliable and accurate at the time of compilation, but no representation or warranty (express or implied) is made, including, without limitation, that the information is complete or timely. Matthews Asia and its affiliates do not accept any liability for losses either direct or consequential caused by the use of this information. 

The views and opinions discussed herein were as of the report date, subject to change and may not reflect the writer›s current views. They are not guarantees of performance or investment results and should not be taken as investment advice. Investment decisions reflect a variety of factors, and the managers reserve the right to change their views about individual stocks, sectors, and the markets at any time. As a result, the views expressed should not be relied upon as a forecast of the Fund›s future investment intent. It should not be assumed that any investment will be profitable or will equal the performance of any securities or any sectors mentioned herein. The information does not constitute a recommendation to buy or sell any securities mentioned.


Sources: Brown Brothers Harriman (Luxembourg) S.C.A, Matthews Asia, FactSet Research Systems, Bloomberg